This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Inflammatory and Immune Disease Animal Model Development Service
Introduction
BioVenic's comprehensive Preclinical Model Development and Validation Services are designed to overcome key R&D pain points. By utilizing diverse animal model construction, rigorous characterization, and downstream in vivo and ex vivo testing, we streamline your non-GLP studies, ensuring high-quality data for robust decision-making.
BioVenic Inflammatory and Immune Disease Animal Model Development Services
Inflammatory and Immune Disease Animal Model Development
BioVenic specializes in developing a broad spectrum of established inflammatory and immune disease models, ranging from common chemically-induced models (e.g., DSS-induced Colitis in mice for IBD) to complex immunity-driven models (e.g., CIA in DBA/1 mice for RA). Crucially, we offer customized model development based on your specific target or pathway.
Inflammatory and Immune Disease Animal Model Validation and Characterization
Successful model development hinges on rigorous validation. BioVenic employs a suite of established methods to confirm the pathological relevance of each model. Common validation methods include: Histopathology (e.g., H&E staining to assess tissue damage and inflammatory cell infiltration), Clinical Scoring (e.g., Disease Activity Index for IBD or Arthritis Scores for CIA), and Biochemical Marker Analysis (e.g., measuring inflammatory cytokines or acute phase proteins in serum).
Inflammatory and Immune Disease Animal Model Sample Collection Services
BioVenic provides precise and systematic sample collection tailored to your experimental needs. This includes the acquisition of various biological specimens such as: Whole blood, serum, and plasma for systemic marker analysis; Target organ tissues (e.g., colon, joints, brain) for pathology and molecular studies; and Isolated cells for downstream ex vivo assays.
Downstream In Vivo and Ex Vivo Study Support on Inflammatory and Immune Disease Animal Models
Leveraging BioVenic's validated animal models, we offer a full range of subsequent experimental services to fully characterize the disease or assess compound efficacy.
Explore BioVenic’s investigative modalities:
- Animal Behavioral Analysis
- Animal Histopathology Service
- Preclinical Animal Pharmacodynamics (PD) Study
- Preclinical Animal Pharmacokinetics (PK) Study
- Animal Cell Biology Service
- Animal lmaging Service
BioVenic’s animal inflammatory and immune disease model related services include:
- Genome-edited Animal Model Development
- Chemically-induced Animal Model Development
- Diet-induced Animal Model Development
- Surgically-induced Animal Model Development
Development Workflow for an Inflammatory and Immune Disease Animal Model
Inflammatory and Immune Disease Animal Models and Application Fields
Table. 1 Common Inflammatory and Immune Disease Animal Models and Application Fields
| Disease Model | Induction Method | Common Animal Species/Strains | Application Field |
|---|---|---|---|
| Psoriasis | Imiquimod (IMQ) topical application | BALB/c, C57BL/6 Mice; SD Rats | Testing anti-inflammatory and anti-proliferative drugs for skin diseases. |
| hIL-23 induction (e.g., ear injection) | C57BL/6 Mice; SD Rats | Studying the role of the IL-23/IL-17 axis in plaque formation. | |
| Rheumatoid Arthritis (RA) | Collagen-Induced Arthritis (CIA) | DBA/1 Mice; Lewis Rats | Investigating the pathology of autoimmune polyarthritis and testing immunomodulators. |
| Collagen Antibody-Induced Arthritis (CAIA) | Mice (e.g., BALB/c) | Faster model for studying innate immune mechanisms and antibody-mediated joint destruction. | |
| Adjuvant-Induced Arthritis (AIA) | Lewis, SD Rats | Classical model for evaluating anti-inflammatory drugs and T-cell-dependent immune responses. | |
| Inflammatory Bowel Disease (IBD) | Dextran Sulfate Sodium (DSS) in drinking water | BALB/c, C57BL/6 Mice; SD Rats | Robust model for acute/chronic colitis, similar to human Ulcerative Colitis (UC). |
| Trinitrobenzene Sulfonic Acid (TNBS) intrarectal administration | BALB/c, C57BL/6 Mice; SD Rats | Model for Crohn's disease-like transmural inflammation. | |
| Oxazolone (OXA) intrarectal administration | BALB/c, SJL Mice | Used to study T-helper 2 (Th2) cell-mediated colitis. | |
| Multiple Sclerosis (MS) / Experimental Autoimmune Encephalomyelitis (EAE) | MOG (Myelin Oligodendrocyte Glycoprotein) peptide + Complete Freund's Adjuvant (CFA) injection | C57BL/6 Mice (chronic EAE); Lewis Rats (acute EAE) | Studying demyelination, neuroinflammation, and testing therapies for MS. |
| Systemic Lupus Erythematosus (SLE) | Spontaneous models (Genetic) | MRL/lpr, NZB/W F1 Mice | Testing treatments for autoimmune disorders characterized by autoantibody production, kidney damage (nephritis), and multi-organ involvement. |
| Pristane or TLR Agonist-induced | C57BL/6, BALB/c Mice | Chemically-induced models for studying specific immune pathways in lupus. | |
| Atopic Dermatitis (AD) | DNFB/DNCB or Oxazolone (OXA) topical application | BALB/c Mice; SD Rats | Modeling contact hypersensitivity and evaluating anti-pruritic and anti-inflammatory agents for eczema. |
| Calcipotriol (MC903) topical application | BALB/c, C57BL/6 Mice | Induced model focusing on Th2 immunity and epidermal barrier dysfunction. | |
| Acute Systemic Inflammation/Sepsis | Lipopolysaccharide (LPS) injection (Endotoxemia) | Mice, Rats | Used to study acute inflammation, shock, and cytokine storm for therapeutic intervention. |
| Cecal Ligation and Puncture (CLP) | Mice, Rats | Polymicrobial sepsis model closely mimicking human septic shock and organ failure. | |
| Acute Local Inflammation / Gout | Monosodium Urate (MSU) crystal injection | Mice, Rats (e.g., Air Pouch, joint cavity) | Modeling acute inflammatory responses, gouty arthritis, and NLRP3 inflammasome activation. |
| Asthma / Respiratory Inflammation | Ovalbumin (OVA) sensitization and challenge | Mice, Rats (e.g., BALB/c, C57BL/6) | Used to study allergic airway inflammation, airway hyperresponsiveness, and test anti-asthma drugs. |
Advantages of BioVenic Inflammatory and Immune Disease Animal Model Development Service
Diverse Existing Model Portfolio
We harness expertise in chemical, genetic, immune-adjuvant, and surgical induction techniques to build a wide array of disease models. BioVenic ensures the meticulous selection of the most suitable animal strain and modeling scheme to meet your specific research goals.
Customization at the Core
Recognizing that no two research projects are identical, BioVenic offers bespoke service. Based on your initial findings and experimental objectives, we strategically select or tailor the most appropriate animal model and pair it with a validated, optimized experimental protocol, ensuring you achieve scientifically sound conclusions and desired outcomes.
Robust Analytical Capabilities
Beyond model construction, BioVenic possesses a comprehensive platform for both validation and downstream analysis. This includes a full suite of animal biochemical profiling, immunohistochemistry, molecular biology, and flow cytometry capabilities to thoroughly characterize the inflammatory phenotype and assess compound impact.
Integrated One-Stop-Shop Service
BioVenic provides a seamless, end-to-end experience. Our service spans from initial model construction and validation through to the execution of your non-GLP in vivo studies and detailed sample analysis. This integrated approach consolidates your research requirements, saving you time and resources.
Case Study: Precision DSS-Induced Ulcerative Colitis & Efficacy
Our facility provides a highly reproducible experimental ulcerative colitis model using a Dextran Sulfate Sodium (DSS) protocol, delivered via precision oral gavage to ensure exact individual dosing and superior consistency over traditional administration methods. We offer rigorous model validation, integrating tracking of body weight fluctuations, stool consistency, and gross hematochezia. Our post-mortem analysis provides definitive quantification of colon length shortening and histological scoring of mucosal architecture integrity and inflammatory infiltration. This standardized platform is specifically designed to evaluate the therapeutic potential of novel anti-inflammatory leads, providing high-resolution data on intestinal epithelial barrier preservation and the targeted suppression of systemic pro-inflammatory cytokines, including TNF-alpha and IL-6.
Fig. 1 Length of Mouse Colon with Different Daily Dosages and Frequencies of DSS1
FAQs
Q: How do you choose the most suitable animal species (Mouse vs. Rat vs. Large Animal) for my specific disease target?
A: The choice is based on your objective. Mice (C57BL/6, BALB/c) are ideal for genetic manipulation and mechanistic studies. Rats (Lewis, SD) are often preferred for surgical procedures and PK/PD due to their size. Large animals are reserved for critical clinical translational assessments like medical device evaluation and long-term safety profiles.
Q: Can you help us study both acute and chronic phases of inflammation?
A: Yes. For example, in IBD, we can establish an acute DSS model (short duration, focusing on cytokine storm) or a chronic, relapsing TNBS model to study disease progression and long-term immune modulation. The model choice is entirely based on the disease phase you wish to investigate.
Q: What validation metrics do you provide to assure the quality of the model developed?
Contact Us
BioVenic's expertise in developing, validating, and applying complex animal models for inflammatory and immune diseases is your strategic advantage in preclinical research. We provide the essential scientific platform-from selecting the ideal genetic or induced model to delivering comprehensive molecular and in vivo data-all tailored to your non-GLP study requirements. Unlock faster, more reliable preclinical insights. Contact us today for a consultation and a detailed quote on your next project.
Reference
- Wang, Dan et al. "Establishment and Evaluation of a Mouse Model of Experimental Ulcerative Colitis Induced by the Gavage Administration of Dextran Sulfate Sodium." Biomedicines vol. 12,8 1764. 5 Aug. 2024. https://doi.org/10.3390/biomedicines12081764. Distributed under Open Access license CC BY 4.0. Without modification.